Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer
Since gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has been utilized in the management of cancers that progress following first-line therapy.While the pathological response to pembrolizumab is favorable, immune related adverse events (irAEs) can be elicited and re...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Marshall University
2021-04-01
|
| Series: | Marshall Journal of Medicine |
| Subjects: |
| _version_ | 1818477805996867584 |
|---|---|
| author | Sydney Graham Emily Sloane Nadim Bou Zgheib |
| author_facet | Sydney Graham Emily Sloane Nadim Bou Zgheib |
| author_sort | Sydney Graham |
| collection | DOAJ |
| description | Since gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has been utilized in the management of cancers that progress following first-line therapy.While the pathological response to pembrolizumab is favorable, immune related adverse events (irAEs) can be elicited and require prompt diagnosis and management based on grading and severity, which can include discontinuation of immunotherapy.Our case concerns a 66-year-old female with recurrent endometrial cancer who was treated with pembrolizumab, and developed inflammatory arthritis following therapy. We provide a succinct review of the pathogenesis and risk factors associated with irAEs, as well as diagnosis and management strategies. |
| first_indexed | 2024-12-10T09:41:33Z |
| format | Article |
| id | doaj.art-b4d6eb0c462b45a3a2a308d477200217 |
| institution | Directory Open Access Journal |
| issn | 2379-9536 |
| language | English |
| last_indexed | 2024-12-10T09:41:33Z |
| publishDate | 2021-04-01 |
| publisher | Marshall University |
| record_format | Article |
| series | Marshall Journal of Medicine |
| spelling | doaj.art-b4d6eb0c462b45a3a2a308d4772002172022-12-22T01:53:59ZengMarshall UniversityMarshall Journal of Medicine2379-95362021-04-017210.33470/2379-9536.1326Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancerSydney Graham0Emily Sloane1Nadim Bou Zgheib2Joan C. Edwards School of Medicine, Marshall UniversityJoan C. Edwards School of Medicine, Marshall UniversityEdwards Comprehensive Cancer CenterSince gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has been utilized in the management of cancers that progress following first-line therapy.While the pathological response to pembrolizumab is favorable, immune related adverse events (irAEs) can be elicited and require prompt diagnosis and management based on grading and severity, which can include discontinuation of immunotherapy.Our case concerns a 66-year-old female with recurrent endometrial cancer who was treated with pembrolizumab, and developed inflammatory arthritis following therapy. We provide a succinct review of the pathogenesis and risk factors associated with irAEs, as well as diagnosis and management strategies.pembrolizumabimmunotherapyimmune-related adverse eventinflammatory arthritisendometrial cancerarthralgia |
| spellingShingle | Sydney Graham Emily Sloane Nadim Bou Zgheib Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer Marshall Journal of Medicine pembrolizumab immunotherapy immune-related adverse event inflammatory arthritis endometrial cancer arthralgia |
| title | Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer |
| title_full | Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer |
| title_fullStr | Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer |
| title_full_unstemmed | Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer |
| title_short | Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer |
| title_sort | arthritis post immunotherapy for endometrial cancer a case report and review of literature on the acute onset of inflammatory arthritis following pd i inhibitor therapy in a patient with recurrent endometrial cancer |
| topic | pembrolizumab immunotherapy immune-related adverse event inflammatory arthritis endometrial cancer arthralgia |
| work_keys_str_mv | AT sydneygraham arthritispostimmunotherapyforendometrialcanceracasereportandreviewofliteratureontheacuteonsetofinflammatoryarthritisfollowingpdiinhibitortherapyinapatientwithrecurrentendometrialcancer AT emilysloane arthritispostimmunotherapyforendometrialcanceracasereportandreviewofliteratureontheacuteonsetofinflammatoryarthritisfollowingpdiinhibitortherapyinapatientwithrecurrentendometrialcancer AT nadimbouzgheib arthritispostimmunotherapyforendometrialcanceracasereportandreviewofliteratureontheacuteonsetofinflammatoryarthritisfollowingpdiinhibitortherapyinapatientwithrecurrentendometrialcancer |